Membranotropic and Antiradical Properties of 2-Nitroxysuccinate 3-Hydroxy-6-Methyl-2-Ethylpyridine
Article
First Online:
- 5 Downloads
We studied membranotropic properties of NO donor 2-nitroxysuccinate 3-hydroxy-6-methyl-2-ethylpyridine and its structural analog succinate 3-hydroxy-6-methyl-2-ethylpyridine (Mexidol). It was shown that the compounds under study are incorporated into modeled membranes and form long-living complexes with pyrene in the region of fatty acid tails of phospholipids. Luminol-amplified chemiluminescence analysis showed that both compounds exhibited antiradical activity and in a concentration of 0.1 mM reduced chemiluminescence intensity by more than 70%. 2-Nitroxysuccinate 3-hydroxy-6-methyl-2-ethylpyridine inhibited catalytic activity of monoamine oxidase A more efficiently than its structural analogue Mexidol.
Key Words
membranotropic activity antioxidants free radicals monoamine oxidase cardiovascular diseasePreview
Unable to display preview. Download preview PDF.
References
- 1.Fedorov BS, Fadeev MA, Varfolomeev VN, Retskij MI, Bliznetsova GN, Neborak EV. Patent RU No. 2394815. Nitroxy-succinate 2-ethyl-6-methyl-3-oxypyridine (versions of use) and method of producing said compound. Bull. No. 20. Published July 20, 2010.Google Scholar
- 2.Poletaeva DA, Kotel’nikova RA, Mischenko DV, Rybkin AY, Smolina AV, Faingol’d II, Troshin PA, Kornev AB, Khakina EA, Kotel’nikov AI. Estimation of membrane activity of water-soluble polysubstituted fullerene derivatives by luminescence methods. Nanotechnologies in Russia. 2012;7(5-6):302-307.CrossRefGoogle Scholar
- 3.Afanas’ev I. ROS and RNS signaling in heart disorders: could antioxidant treatment be successful? Oxid. Med. Cell. Longev. 2011;2011. 293769. doi: 10.1155/2011/293769.CrossRefGoogle Scholar
- 4.Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Deliv. Rev. 2008;60(13-14):1527-1533.CrossRefGoogle Scholar
- 5.Corbineau S, Breton M, Mialet-Perez J, Costemale-Lacoste JF. Major depression and heart failure: Interest of monoamine oxidase inhibitors. Int. J. Cardiol. 2017;247:1-6.CrossRefGoogle Scholar
- 6.Di Meo S, Venditti P, Piro M. C, De Leo T. Enhanced luminescence study of liver homogenate response to oxidative stress. Arch. Physiol. Biochem. 1995;103(2):187-195.CrossRefGoogle Scholar
- 7.Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr. Rev. 2012;70(5):257-265.CrossRefGoogle Scholar
- 8.Mialet-Perez J, Bianchi P, Kunduzova O, Parini A. New insights on receptor-dependent and monoamine oxidase-dependent effects of serotonin in the heart. J. Neural. Transm. (Vienna). 2007;114(6):823-827.CrossRefGoogle Scholar
- 9.Mocellin S. Nitric oxide: cancer target or anticancer agent? Curr. Cancer Drug Targets. 2009;9(2):214-236.CrossRefGoogle Scholar
- 10.Nikolaeva NS, Aksinenko AY, Kinzirsky AS, Soldatova YV, Smolina AV, Sokolov VB, Kotelnikova RA, Shtolko VN, Kotelnikov AI. Effect of fluorinated tetrahydrocarbazole derivatives on the enzymes of oxidative deamination of biogenic amines and on the process of lipid peroxidation. Russ. Chem. Bull. 2017;66(5):870-874.CrossRefGoogle Scholar
- 11.Peetla C, Stine A, Labhasetwar V. Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol. Pharm. 2009;6(5):1264-1276.CrossRefGoogle Scholar
- 12.Wanstall JC, Jeffery TK, Gambino A, Lovren F, Triggle CR. Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br. J. Pharmacol. 2001;134(3):463-472.CrossRefGoogle Scholar
- 13.Witte MB, Barbul A. Role of nitric oxide in wound repair. Am. J. Surg. 2002;183(4):406-412.CrossRefGoogle Scholar
- 14.Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 2006;7(4):295-309.CrossRefGoogle Scholar
Copyright information
© Springer Science+Business Media, LLC, part of Springer Nature 2019